title: Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.
abstract: Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy. Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels. Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity. For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study. A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages. Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel. In the latter group, brain edema was markedly reduced and dealt medically. Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.
authors.affiliation: Department of Neurosurgery, HELIOS Klinikum Berlin, Klinikum Buch, Hobrechtsfelder Chaussee 96, 13125 Berlin, Germany. keckardstein@berlin.helios-kliniken.de
authors.forename: Kajetan L
authors.initials: KL
authors.lastname: von Eckardstein
authors.forename: Regina
authors.initials: R
authors.lastname: Reszka
authors.forename: Jürgen C W
authors.initials: JC
authors.lastname: Kiwit
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000134:cerebrospinal fluid; D001929:Brain Edema / Q000139:chemically induced; D001932:Brain Neoplasms / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000134:cerebrospinal fluid; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000134:cerebrospinal fluid; D010865:Pilot Projects; D016019:Survival Analysis
chemical_list: D004337:Drug Carriers; D016190:Carboplatin; D017239:Paclitaxel